Ipamorelin is frequently described in the preclinical literature as the first "selective" growth hormone secretagogue. This review examines what that selectivity actually refers to at the receptor level, and how controlled animal and cell-based studies distinguish it from earlier growth hormone–releasing peptides. All discussion concerns research findings only.

The receptor-first turn in secretagogue research

Synthetic growth hormone secretagogues (GHSs) predate the discovery of their natural ligand. Small peptides such as the growth hormone–releasing peptides (GHRP-6, GHRP-2) and non-peptide mimetics such as MK-0677 were shown to release growth hormone (GH) from the pituitary through a pathway distinct from hypothalamic growth hormone–releasing hormone (GHRH).⁴ These compounds were characterized before anyone knew what endogenous molecule they were imitating, which is unusual: pharmacology normally follows physiology, not the reverse.

The turning point was the molecular identification of the growth hormone secretagogue receptor, a G-protein-coupled receptor expressed in a biologically active type-1a form (GHSR-1a) and a truncated, inactive type-1b form. Its transcript was detected in human somatotroph tumors and rat pituitary cell lines, confirming that the receptor was present in the tissues where GH is made.³ In 1999, the endogenous ligand was purified from rat stomach as a 28-amino-acid acylated peptide and named ghrelin, closing the loop between the synthetic secretagogues and a real hormonal system.¹

Once the receptor was defined, secretagogue research shifted from asking "does this peptide release GH?" to "which receptor does it engage, and what else does it activate?" Within that receptor-focused framework, ipamorelin became a reference compound, because it was introduced explicitly as a molecule that engages the GHSR pathway while sparing other pituitary and adrenal outputs.²

How ipamorelin receptor pharmacology produces signaling precision

Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, that was identified during a chemistry program searching for compounds lacking the central Ala-Trp dipeptide of GHRP-1. In primary rat pituitary cells it released GH with a potency and efficacy similar to GHRP-6 (reported EC50 around 1.3 nmol/L), placing it firmly in the nanomolar range typical of GHSR agonists.² The relevant point for "precision" is not that it is unusually potent, but where that potency is directed.

Pharmacological profiling in the founding study used GHRP and GHRH receptor antagonists to dissect the pathway. GHRP-type antagonists blocked the response while GHRH antagonists did not, indicating that ipamorelin acts through the GHRP-like (GHSR) receptor rather than the GHRH receptor.² This antagonist logic is the experimental basis for describing its signaling as "receptor-defined": the observed GH release can be attributed to a specific receptor rather than to diffuse pituitary stimulation.

Three experimental observations recur across the primary literature:

• Structural refinement of the GHRP scaffold enhanced GHSR engagement while reducing off-target endocrine activity.²
• Cell assays showed nanomolar GH-releasing potency without evidence of broad pituitary activation.²
• Antagonist experiments confirmed a GHRP-like receptor mechanism operating independently of the GHRH pathway.²

Because these dose-response and antagonist experiments were replicated across rat pituitary cells, anaesthetized rats and conscious swine, ipamorelin is often used as a comparator when investigators want a GHSR-1a agonist whose downstream endocrine footprint is comparatively narrow. Related synthetic secretagogues such as sermorelin, a GHRH analog, engage a different receptor entirely, which is why side-by-side receptor pharmacology matters when designing a study.

Endocrine selectivity versus legacy secretagogues

The claim that most clearly differentiates ipamorelin from earlier secretagogues is endocrine selectivity: in animal models it raises GH without measurably raising adrenocorticotropic hormone (ACTH) or cortisol. In the specificity experiments conducted in swine, none of the tested secretagogues altered FSH, LH, prolactin or TSH, but GHRP-6 and GHRP-2 both increased ACTH and cortisol. Ipamorelin did not raise ACTH or cortisol above levels seen after GHRH, even at doses more than 200-fold above its ED50 for GH release.²

That contrast is meaningful because activation of the hypothalamic-pituitary-adrenal (HPA) axis by other GHRPs is well documented. GHRP-6, for example, stimulated ACTH and cortisol release in a controlled clinical study of patients with Cushing's disease, with responses comparable to the vasopressin analog DDAVP.¹⁰ A secretagogue that co-activates the HPA axis introduces a confounding hormonal variable into any experiment intended to isolate GH-dependent effects.

Values summarize comparative observations reported by Raun and colleagues in rat and swine models.² They are not human dosing data.

Selective GH activation

Across the reported models, ipamorelin stimulated GH release without altering ACTH, cortisol, gonadotropins, prolactin or TSH, a pattern consistent with signaling constrained to somatotroph populations rather than diffuse pituitary activation.²

Limited HPA engagement

Where legacy secretagogues recruit the corticotroph-adrenal axis alongside GH release, ipamorelin maintained minimal ACTH and cortisol activation even at high multiples of its GH-releasing dose.² This is the observation most often cited as the operational meaning of its "selectivity."

Reduced endocrine crosstalk

Head-to-head comparisons showed similar GH output between ipamorelin and earlier secretagogues, but only ipamorelin avoided parallel HPA stimulation, reducing confounding hormonal interactions in controlled experiments.²

Glucocorticoid-driven musculoskeletal catabolism

A frequently referenced application of ipamorelin in preclinical work is as a probe of GH-dependent tissue maintenance under catabolic stress. Chronic glucocorticoid exposure suppresses bone formation and muscle performance, and one adult-rat study asked whether a selective GHS could counteract that decline.⁶

In that study, 8-month-old female rats received methylprednisolone, ipamorelin, or both for three months. Compared with glucocorticoid alone, the combination showed a roughly four-fold higher periosteal bone formation rate and significantly greater maximum tetanic tension in the calf muscles.⁶ The findings describe attenuation of steroid-associated structural and functional decline in a rodent system, not a human outcome.

Three mechanistic threads run through this work:

Periosteal preservation. Glucocorticoids compromise periosteal activity and cortical integrity; co-administration of ipamorelin restored bone formation indices toward control levels in the treated animals.⁶

Muscle force maintenance. Prolonged steroid exposure reduces skeletal muscle contractile function; treated animals retained higher isometric tetanic force, indicating preserved muscle performance under ongoing catabolic load.⁶

Focused GH action. These musculoskeletal effects tracked with a GH-secretagogue response rather than widespread endocrine activation, consistent with the selectivity profile established in the founding pharmacology.²

How controlled bone studies quantify skeletal specificity

Beyond the catabolic model, a dedicated bone-growth study quantified how localized the skeletal response is. Adult female rats received subcutaneous ipamorelin at 0, 18, 90 or 450 µg/day, three times daily for 15 days, with longitudinal growth rate measured by tetracycline labelling in the proximal tibia.⁵

Longitudinal growth rate increased dose-dependently, from 42 µm/day in vehicle animals to 44, 50 and 52 µm/day across the ascending doses, with a parallel effect on body-weight gain.⁵ The instructive part is what did not change: total IGF-I, IGF binding proteins and serum markers of bone formation and resorption were unaffected, and tartrate-resistant acid phosphatase-positive osteoclast counts did not shift significantly.⁵

Taken together, the growth response appears to reflect targeted activity at the epiphyseal growth plate rather than a broad rise in circulating IGF-I or a resorptive remodelling signal. That combination, a measurable skeletal effect without matching systemic endocrine markers, is precisely why ipamorelin is used as a controlled experimental tool for dissecting GH-linked skeletal biology in rodents. The original authors were explicit that any translational relevance to growth-retarded children would require future clinical studies, which underscores how preliminary the human picture remains.⁵

Biased signaling and the limits of "clean" selectivity

The word "selective" is convenient shorthand, but the receptor it acts on is anything but simple. GHSR-1a couples to multiple pathways, including Gαq, Gαi/o and Gα12/13, and recruits β-arrestin, and it displays unusually high basal constitutive activity even without a ligand.⁷ Different ligands can bias the receptor toward one pathway over another, a phenomenon known as functional selectivity or biased agonism.

Studies characterizing GHSR-1a ligands have shown that agonists, antagonists and inverse agonists engage these downstream arms to different degrees; some ligands favor G-protein signaling while others preferentially modulate β-arrestin recruitment.⁸ This matters for interpreting ipamorelin research: describing a compound as "GHSR-selective" specifies the receptor but not necessarily which intracellular pathway dominates, and the somatotroph-focused GH release observed in vivo need not map cleanly onto a single signaling branch.

The broader receptor pharmacology also cautions against over-reading endocrine tidiness. Because GHSR-1a is a target of interest for metabolic and gastrointestinal research, the same receptor that mediates GH release is implicated in appetite, gastric motility and reward pathways.⁹ Selectivity for GH output at the pituitary does not imply the receptor is silent elsewhere; it means the specific readout measured in a given experiment was constrained. Honest interpretation keeps those two claims separate.

Why selectivity matters for experimental design

For investigators, the practical value of a receptor-selective secretagogue is experimental cleanliness. If a compound raises GH without co-activating the HPA axis, any downstream musculoskeletal, metabolic or behavioral readout is easier to attribute to GH signaling rather than to a cortisol confound. That is the design rationale behind using ipamorelin as a comparator against multi-pathway secretagogues.

Several interpretive limits apply, and the primary literature states them plainly. First, the evidence is species-bound: rat and swine endocrine regulation does not fully replicate other systems, and dose regimens and study durations constrain cross-study comparison.² Second, apparent "selectivity" is assay-dependent, because a receptor with biased signaling and constitutive activity can produce different profiles depending on which pathway is measured.⁷ Third, the skeletal and catabolic findings, while consistent, come from a small number of rodent studies and were framed by their authors as hypothesis-generating rather than conclusive.⁵

Researchers comparing GH secretagogues in a controlled protocol sometimes hold receptor class constant and vary only the ligand; combination reagents such as the CJC-1295 (No DAC) + Ipamorelin blend pair a GHRH analog with a GHSR agonist, which is a different pharmacological question from studying ipamorelin alone. Choosing the right comparator is part of designing an interpretable experiment.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.